Community Acquired Pneumonia – Pipeline Review, 2019

Community acquired pneumonia is defined as pneumonia that an individual acquires outside the hospital or healthcare settings. Community acquired pneumonia is among the common infectious diseases and an important determinant of morbidity and mortality of any country. It is caused by pathogens such as Streptococcus pneumoniae, Mycoplasma pneumonia, Chlamydia pneumonia, Haemophilus influenzae, Legionella species, and viruses. Common symptoms of community acquired pneumonia are cough, fever, pleuritic chest pain, heavy sputum, dyspnea, and others.

Current treatment of community acquired pneumonia include antibiotics and sometimes anti-fungal and anti-viral drugs. Antibiotics prescribed for community acquired pneumonia are Macrolides, fluoroquinolones, doxycycline, amoxicillin, cefpodoxime, and others. In certain conditions, antiviral drugs such as oseltamivir or zanamivir can also be prescribed for the treatment.

Owing to the active government support and growing awareness regarding community health, the demand for drugs against community acquired pneumonia has increased. This has also initiated many clinical studies by pharmaceutical companies and research centers for the development of new drugs. For instance; CAL02, which is being studied by Combioxin SA, is currently in phase 1 clinical trials for the treatment of community acquired pneumonia.

At present, around 45% of the pipeline candidates for community acquired pneumonia are in phase 3 clinical stage. More than half of the studies are sponsored by academic research institutes.

Report Description

The report on ‘Community Acquired Pneumonia – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Community Acquired Pneumonia. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Community Acquired Pneumonia.

The report on ‘Community Acquired Pneumonia – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• Thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target


• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration


• Overview of dormant and discontinued pipeline products


• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products


• Overview of the latest developments; news articles, press releases and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.


• Desk research sources includes global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on comprehensive overview of the R&D activity and pipeline products for Community Acquired Pneumonia


• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players


• Identify the focus of leading players in relation to R&D for Community Acquired Pneumonia


• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business


• Analyse the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary